PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: CUSTOMER LANDSCAPE PART 07: MARKET SEGMENTATION BY ROA • Market segmentation by RoA • Comparison by RoA • Oral HDAC inhibitors - Market size and forecast 2018-2023 • Parenteral HDAC inhibitors - Market size and forecast 2018-2023 • Market opportunity by RoA PART 08: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • CELGENE CORPORATION • Merck & Co., Inc. • Novartis AG • Shenzhen Chipscreen Biosciences Co., Ltd. • Spectrum Pharmaceuticals, Inc. PART 14: APPENDIX • Research methodology • List of abbreviations PART 15: EXPLORE TECHNAVIO   Exhibit 01: Global pharmaceuticals market Exhibit 02: Segments of global pharmaceuticals market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Customer landscape Exhibit 18: RoA - Market share 2018-2023 (%) Exhibit 19: Comparison by RoA Exhibit 20: Oral HDAC inhibitors - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Oral HDAC inhibitors: Pipeline overview Exhibit 22: Oral HDAC inhibitors - Year-over-year growth 2019-2023 (%) Exhibit 23: Parenteral HDAC inhibitors - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Parenteral HDAC inhibitors - Year-over-year growth 2019-2023 (%) Exhibit 25: Market opportunity by RoA Exhibit 26: Market share by geography 2018-2023 (%) Exhibit 27: Geographic comparison Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 29: North America - Year-over-year growth 2019-2023 (%) Exhibit 30: Top 3 countries in North America Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 32: Europe - Year-over-year growth 2019-2023 (%) Exhibit 33: Top 3 countries in Europe Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 35: Asia - Year-over-year growth 2019-2023 (%) Exhibit 36: Top 3 countries in Asia Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 38: ROW - Year-over-year growth 2019-2023 (%) Exhibit 39: Top 3 countries in ROW Exhibit 40: Key leading countries Exhibit 41: Market opportunity Exhibit 42: Prevalence of top 5 cancers newly reported in US 2015 Exhibit 43: Pipeline of combination therapies - Syndax Exhibit 44: Treatment costs of HDAC inhibitors Exhibit 45: Alternative treatment options for oncology conditions Exhibit 46: Side effects of HDAC Exhibit 47: Impact of drivers and challenges Exhibit 48: Some strategic alliances in global HDAC inhibitors market Exhibit 49: drugs with respect to their cancer indications and expanded indications Exhibit 50: Vendor landscape Exhibit 51: Landscape disruption Exhibit 52: Vendors covered Exhibit 53: Vendor classification Exhibit 54: Market positioning of vendors Exhibit 55: CELGENE CORPORATION - Vendor overview Exhibit 56: CELGENE CORPORATION - Business segments Exhibit 57: CELGENE CORPORATION - Organizational developments Exhibit 58: CELGENE CORPORATION - Geographic focus Exhibit 59: CELGENE CORPORATION - Key offerings Exhibit 60: CELGENE CORPORATION - Key customers Exhibit 61: Merck & Co., Inc. - Vendor overview Exhibit 62: Merck & Co., Inc. - Business segments Exhibit 63: Merck & Co., Inc. - Organizational developments Exhibit 64: Merck & Co., Inc. - Geographic focus Exhibit 65: Merck & Co., Inc. - Segment focus Exhibit 66: Merck & Co., Inc. - Key offerings Exhibit 67: Merck & Co., Inc. - Key customers Exhibit 68: Novartis AG - Vendor overview Exhibit 69: Novartis AG - Business segments Exhibit 70: Novartis AG - Organizational developments Exhibit 71: Novartis AG - Geographic focus Exhibit 72: Novartis AG - Segment focus Exhibit 73: Novartis AG - Key offerings Exhibit 74: Novartis AG - Key customers Exhibit 75: Shenzhen Chipscreen Biosciences Co., Ltd. - Vendor overview Exhibit 76: Shenzhen Chipscreen Biosciences Co., Ltd. - Organizational developments Exhibit 77: Shenzhen Chipscreen Biosciences Co., Ltd. - Key offerings Exhibit 78: Shenzhen Chipscreen Biosciences Co., Ltd. - Key customers Exhibit 79: Spectrum Pharmaceuticals, Inc. - Vendor overview Exhibit 80: Spectrum Pharmaceuticals, Inc. - Business segments Exhibit 81: Spectrum Pharmaceuticals, Inc. - Organizational developments Exhibit 82: Spectrum Pharmaceuticals, Inc. - Geographic focus Exhibit 83: Spectrum Pharmaceuticals, Inc. - Key offerings Exhibit 84: Spectrum Pharmaceuticals, Inc. - Key customers Exhibit 85: Validation techniques employed for market sizing

CELGENE CORPORATION Merck & Co., Inc. Novartis AG Shenzhen Chipscreen Biosciences Co., Ltd. Spectrum Pharmaceuticals, Inc.